• Je něco špatně v tomto záznamu ?

Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II

MHM. Oonk, B. Slomovitz, PJW. Baldwin, HC. van Doorn, J. van der Velden, JA. de Hullu, KN. Gaarenstroom, BFM. Slangen, I. Vergote, M. Brännström, EBL. van Dorst, WJ. van Driel, RH. Hermans, D. Nunns, M. Widschwendter, D. Nugent, CM. Holland, A....

. 2021 ; 39 (32) : 3623-3632. [pub] 20210825

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze II, srovnávací studie, časopisecké články, multicentrická studie, práce podpořená grantem, webové vysílání

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003213

Grantová podpora
UG1 CA233193 NCI NIH HHS - United States
UG1 CA233331 NCI NIH HHS - United States

PURPOSE: The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). METHODS: GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. RESULTS: From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (≤ 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL. CONCLUSION: Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients with SN macrometastasis, radiotherapy with a total dose of 50 Gy resulted in more isolated groin recurrences compared with IFL.

1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Aarhus University Hospital Aarhus Denmark

Amsterdam University Medical Center Amsterdam the Netherlands

Cambridge University Hospitals NHS Foundation Trust Cambridge United Kingdom

Capio Part of Ramsey Santé Hellerup Denmark

Catharina Ziekenhuis Eindhoven the Netherlands

Center of Gynecological Oncology Amsterdam The Netherlands Cancer Institute Amsterdam the Netherlands

Central Hospital Karlstad Karlstad Sweden

CHUM Université de Montréal Montréal Quebec Canada

Dalhousie University Halifax Nova Scotia Canada

Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam the Netherlands

James Cook University Hospital South Tees NHS Foundation Trust Middlesbrough United Kingdom

Jena University Hospital Friedrich Schiller University Jena Germany

Leeds Teaching Hospitals NHS Trust St James' University Hospital Leeds United Kingdom

Leiden University Medical Center Leiden the Netherlands

Leuven Cancer Institute Leuven Belgium

Linköping University Linköping Sweden

Maastricht University Medical Center Maastricht the Netherlands

Manchester University NHS Foundation Trust St Marys Hospital Manchester United Kingdom

MD Anderson Cancer Center Houston TX

Medical University Graz Graz Austria

Memorial Sloan Kettering Cancer Center New York NY

Morristown Medical Center Morristown NJ

Mount Sinai Medical Center Miami Beach FL

Norfolk and Norwich University Hospital NHS Trust Norwich United Kingdom

Nottingham University Hospitals NHS Trust Nottingham United Kingdom

Ohio State University Comprehensive Cancer Center James Cancer Hospital Columbus OH

Oslo University Hospital Radiumhospitalet Oslo Norway

Radboud University Medical Center Nijmegen the Netherlands

Royal Surrey NHS Foundation Trust Guildford United Kingdom

Sahlgrenska Academy University of Gothenburg Göteborg Sweden

Singleton Hospital Swansea United Kingdom

Skåne University Hospital Lund University Lund Sweden

St Josephs Hospital and Medical Center Phoenix AZ

St Michaels Hospital Bristol United Kingdom

Stephenson Cancer Center University of Oklahoma Oklahoma City OK

UC Irvine Health Medical Center Orange CA

UCL EGA Institute for Women's Health University College London London United Kingdom

University Hospital of Wales Cardiff United Kingdom

University Hospital Pilsen Charles University Faculty of Medicine Pilsen Czech Republic

University Hospitals of Derby and Burton Derby United Kingdom

University Medical Center Groningen University of Groningen Groningen the Netherlands

University Medical Center Utrecht Utrecht the Netherlands

University of Birmingham Birmingham United Kingdom

University of Minnesota Minneapolis MN

University of North Carolina Chapel Hill NC

University of Toronto Toronto Ontario Canada

Uppsala University Uppsala Sweden

UT Southwestern Medical Center Dallas TX

West Kent Cancer Centre Maidstone Hospital Maidstone United Kingdom

Wolfson Institute of Population Health Queen Mary University of London London United Kingdom

Women and Infants Hospital of Rhode Island Providence RI

Women's Cancer Center of Nevada Las Vegas NV

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003213
003      
CZ-PrNML
005      
20220127150552.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.21.00006 $2 doi
035    __
$a (PubMed)34432481
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Oonk, Maaike H M $u University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
245    10
$a Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II / $c MHM. Oonk, B. Slomovitz, PJW. Baldwin, HC. van Doorn, J. van der Velden, JA. de Hullu, KN. Gaarenstroom, BFM. Slangen, I. Vergote, M. Brännström, EBL. van Dorst, WJ. van Driel, RH. Hermans, D. Nunns, M. Widschwendter, D. Nugent, CM. Holland, A. Sharma, PA. DiSilvestro, R. Mannel, D. Boll, D. Cibula, A. Covens, D. Provencher, IB. Runnebaum, D. Luesley, P. Ellis, TJ. Duncan, MY. Tjiong, DJ. Cruickshank, P. Kjølhede, CF. Levenback, J. Bouda, KE. Kieser, C. Palle, NM. Spirtos, DM. O'Malley, MM. Leitao, MA. Geller, K. Dhar, V. Asher, K. Tamussino, DH. Tobias, C. Borgfeldt, JS. Lea, J. Bailey, M. Lood, B. Eyjolfsdottir, S. Attard-Montalto, KS. Tewari, R. Manchanda, PT. Jensen, P. Persson, L. Van Le, H. Putter, GH. de Bock, BJ. Monk, CL. Creutzberg, AGJ. van der Zee
520    9_
$a PURPOSE: The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). METHODS: GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. RESULTS: From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (≤ 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL. CONCLUSION: Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients with SN macrometastasis, radiotherapy with a total dose of 50 Gy resulted in more isolated groin recurrences compared with IFL.
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a lymfadenektomie $x škodlivé účinky $x mortalita $7 D008197
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mikrometastázy $7 D061206
650    _2
$a staging nádorů $7 D009367
650    _2
$a prospektivní studie $7 D011446
650    12
$a dávka záření $7 D011829
650    _2
$a sentinelová uzlina $x patologie $x účinky záření $x chirurgie $7 D000071036
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a nádory vulvy $x mortalita $x patologie $x terapie $7 D014846
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a webové vysílání $7 D057405
700    1_
$a Slomovitz, Brian $u Mount Sinai Medical Center, Miami Beach, FL
700    1_
$a Baldwin, Peter J W $u Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
700    1_
$a van Doorn, Helena C $u Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands
700    1_
$a van der Velden, Jacobus $u Amsterdam University Medical Center, Amsterdam, the Netherlands
700    1_
$a de Hullu, Joanne A $u Radboud University Medical Center, Nijmegen, the Netherlands
700    1_
$a Gaarenstroom, Katja N $u Leiden University Medical Center, Leiden, the Netherlands
700    1_
$a Slangen, Brigitte F M $u Maastricht University Medical Center+, Maastricht, the Netherlands
700    1_
$a Vergote, Ignace $u Leuven Cancer Institute, Leuven, Belgium
700    1_
$a Brännström, Mats $u Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
700    1_
$a van Dorst, Eleonora B L $u University Medical Center Utrecht, Utrecht, the Netherlands
700    1_
$a van Driel, Willemien J $u Center of Gynecological Oncology Amsterdam, The Netherlands Cancer Institute, Amsterdam, the Netherlands
700    1_
$a Hermans, Ralph H $u Catharina Ziekenhuis Eindhoven, the Netherlands
700    1_
$a Nunns, David $u Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
700    1_
$a Widschwendter, Martin $u UCL EGA Institute for Women's Health, University College London, London, United Kingdom
700    1_
$a Nugent, David $u Leeds Teaching Hospitals NHS Trust, St James' University Hospital, Leeds, United Kingdom
700    1_
$a Holland, Cathrine M $u Manchester University NHS Foundation Trust-St Marys Hospital, Manchester, United Kingdom
700    1_
$a Sharma, Aarti $u University Hospital of Wales, Cardiff, United Kingdom
700    1_
$a DiSilvestro, Paul A $u Women and Infants Hospital of Rhode Island, Providence, RI
700    1_
$a Mannel, Robert $u Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK
700    1_
$a Boll, Dorry $u Catharina Ziekenhuis Eindhoven, the Netherlands
700    1_
$a Cibula, David $u First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Covens, Al $u University of Toronto, Toronto, Ontario, Canada
700    1_
$a Provencher, Diane $u CHUM, Université de Montréal, Montréal, Quebec, Canada
700    1_
$a Runnebaum, Ingo B $u Jena University Hospital, Friedrich Schiller University, Jena, Germany
700    1_
$a Luesley, David $u University of Birmingham, Birmingham, United Kingdom
700    1_
$a Ellis, Patricia $u Royal Surrey NHS Foundation Trust, Guildford, United Kingdom
700    1_
$a Duncan, Timothy J $u Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom
700    1_
$a Tjiong, Ming Y $u Amsterdam University Medical Center, Amsterdam, the Netherlands
700    1_
$a Cruickshank, Derek J $u James Cook University Hospital, South Tees NHS Foundation Trust, Middlesbrough, United Kingdom
700    1_
$a Kjølhede, Preben $u Linköping University, Linköping, Sweden
700    1_
$a Levenback, Charles F $u MD Anderson Cancer Center, Houston, TX
700    1_
$a Bouda, Jiri $u University Hospital Pilsen, Charles University, Faculty of Medicine, Pilsen, Czech Republic
700    1_
$a Kieser, Katharina E $u Dalhousie University, Halifax, Nova Scotia, Canada
700    1_
$a Palle, Connie $u Capio, Part of Ramsey Santé, Hellerup, Denmark
700    1_
$a Spirtos, Nicola M $u Women's Cancer Center of Nevada, Las Vegas, NV
700    1_
$a O'Malley, David M $u Ohio State University Comprehensive Cancer Center-James Cancer Hospital, Columbus, OH
700    1_
$a Leitao, Mario M $u Memorial Sloan Kettering Cancer Center, New York, NY
700    1_
$a Geller, Melissa A $u University of Minnesota, Minneapolis, MN
700    1_
$a Dhar, Kalyan $u Singleton Hospital, Swansea, United Kingdom
700    1_
$a Asher, Viren $u University Hospitals of Derby and Burton, Derby, United Kingdom
700    1_
$a Tamussino, Karl $u Medical University Graz, Graz, Austria
700    1_
$a Tobias, Daniel H $u Morristown Medical Center, Morristown, NJ
700    1_
$a Borgfeldt, Christer $u Skåne University Hospital, Lund University, Lund, Sweden
700    1_
$a Lea, Jayanthi S $u UT Southwestern Medical Center, Dallas, TX
700    1_
$a Bailey, Jo $u St Michaels Hospital, Bristol, United Kingdom
700    1_
$a Lood, Margareta $u Central Hospital Karlstad, Karlstad, Sweden
700    1_
$a Eyjolfsdottir, Brynhildur $u Oslo University Hospital, Radiumhospitalet, Oslo, Norway
700    1_
$a Attard-Montalto, Stephen $u West Kent Cancer Centre, Maidstone Hospital, Maidstone, United Kingdom
700    1_
$a Tewari, Krishnansu S $u UC Irvine Health Medical Center, Orange, CA
700    1_
$a Manchanda, Ranjit $u Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom
700    1_
$a Jensen, Pernille T $u Aarhus University Hospital, Aarhus, Denmark
700    1_
$a Persson, Par $u Uppsala University, Uppsala, Sweden
700    1_
$a Van Le, Linda $u University of North Carolina, Chapel Hill, NC
700    1_
$a Putter, Hein $u Leiden University Medical Center, Leiden, the Netherlands
700    1_
$a de Bock, Geertruida H $u University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
700    1_
$a Monk, Bradley J $u St Josephs Hospital and Medical Center, Phoenix, AZ
700    1_
$a Creutzberg, Carien L $u Leiden University Medical Center, Leiden, the Netherlands
700    1_
$a van der Zee, Ate G J $u University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
773    0_
$w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 39, č. 32 (2021), s. 3623-3632
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34432481 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127150548 $b ABA008
999    __
$a ok $b bmc $g 1750849 $s 1154362
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 39 $c 32 $d 3623-3632 $e 20210825 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
GRA    __
$a UG1 CA233193 $p NCI NIH HHS $2 United States
GRA    __
$a UG1 CA233331 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace